HSP70 regulates cytokine secretion by acting on monocytes and further affects the clinical outcome of hemophagocytic lymphohistiocytosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051430

Enrollment

Unknown

Registered

2021-09-23

Start date

2021-10-15

Completion date

Unknown

Last updated

2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemophagocytic lymphohistiocytosis

Interventions

HLH group:none

severe sepsis group:None

healthy control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HLH patients with definite diagnosis and continuous treatment in our hospital will be rolled in.

Exclusion criteria

Exclusion criteria: HLH patients lost to follow-up.

Design outcomes

Primary

Measure	Time frame
HSP70;	—

Secondary

Measure	Time frame
IL-6;IL-10;IFN-?;	—

Countries

China

Contacts

Public ContactLu Wenjie

Wuhan Children's Hospital

luwj1007@163.com+86 13297001518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026